{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:27:39Z","timestamp":1795040859406,"version":"4.10.2"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.comppsych.2021.152244","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:40:21Z","timestamp":1621384821000},"page":"152244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review"],"prefix":"10.1016","volume":"109","author":[{"given":"Anna","family":"La Salvia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Portigliatti Pomeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Trevisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parlagreco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco Luigi","family":"Picci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.comppsych.2021.152244_bb0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.comppsych.2021.152244_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000376","article-title":"Carcinoid-syndrome: recent advances, current status and controversies","volume":"25","author":"Ito","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.comppsych.2021.152244_bb0015","first-page":"1131","article-title":"5Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology","author":"Kidd","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0020","first-page":"25458","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.comppsych.2021.152244_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Berruti a, on behalf of the ESMO guidelines committee, Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.comppsych.2021.152244_bb0030","doi-asserted-by":"crossref","first-page":"e490s","DOI":"10.6061\/clinics\/2018\/e490s","article-title":"Carcinoid syndrome: update on the pathophysiology and treatment","volume":"73","author":"Rubin de Celis Ferrari","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"issue":"10","key":"10.1016\/j.comppsych.2021.152244_bb0035","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.comppsych.2021.152244_bb0040","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1572-0241.2004.40507.x","article-title":"Carcinoid tumors and fibrosis: an association with no explanation","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0045","first-page":"257","article-title":"Advances in the management of patients with carcinoid syndrome","volume":"15","author":"Kulke","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.comppsych.2021.152244_bb0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.comppsych.2021.152244_bb0060","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.comppsych.2021.152244_bb0065","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.comppsych.2021.152244_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.2017-0284","article-title":"Patient-reported symptom control of diarrhea and Flushing in patients with neuroendocrine tumors treated with Lanreotide Depot\/autogel: results from a randomized, placebo-controlled, double-blind and 32-week open-label study","volume":"23","author":"Fisher","year":"2018","journal-title":"Oncologist."},{"key":"10.1016\/j.comppsych.2021.152244_bb0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide autogel\/Depot for carcinoid syndrome: an international observational study","volume":"48","author":"Ruszniewski","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0080","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.comppsych.2021.152244_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.comppsych.2021.152244_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.comppsych.2021.152244_bb0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.comppsych.2021.152244_bb0100","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.comppsych.2021.152244_bb0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1245\/s10434-016-5591-7","article-title":"Initial treatment of Unresectable neuroendocrine tumor liver metastases with Transarterial chemoembolization using Streptozotocin: a 20-year experience","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hpb.12326","article-title":"Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-liver-metastases consensus conference","volume":"17","author":"Kennedy","year":"2015","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.comppsych.2021.152244_bb0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.suronc.2012.07.001","article-title":"Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review","volume":"21","author":"Yang","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ajco.12438","article-title":"Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes","volume":"12","author":"Pericleous","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0125","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical Management of Small Bowel Neuroendocrine Tumors: consensus guidelines of the north American neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas."},{"issue":"9","key":"10.1016\/j.comppsych.2021.152244_bb0130","first-page":"3695","article-title":"Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden","volume":"24","author":"Pearman","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.comppsych.2021.152244_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0098-2997(83)90005-5","article-title":"Biochemistry of tryptophan in health and disease","volume":"6","author":"Bender","year":"1983","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.comppsych.2021.152244_bb0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1097540","article-title":"Tryptophan hydroxylase-2 controls brain serotonin synthesis","volume":"305","author":"Zhang","year":"2004","journal-title":"Science."},{"key":"10.1016\/j.comppsych.2021.152244_bb0145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1749-6632.1994.tb17296.x","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"733","author":"Kvols","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.comppsych.2021.152244_bb0150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000440621","article-title":"Niacin (vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor","volume":"103","author":"Bouma","year":"2016","journal-title":"Neuroendocrinology."},{"issue":"Suppl. 15","key":"10.1016\/j.comppsych.2021.152244_bb0155","first-page":"4","volume":"59","author":"Murphy","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"1615","key":"10.1016\/j.comppsych.2021.152244_bb0160","doi-asserted-by":"crossref","first-page":"20120435","DOI":"10.1098\/rstb.2012.0435","article-title":"Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive\u2013 compulsive disorder as an example of overlapping clinical and genetic heterogeneity","volume":"368","author":"Murphy","year":"2013","journal-title":"Phil Trans R Soc"},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0165","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00268-010-0404-9","article-title":"Impairment of cognitive function reported by patients suffering from carcinoid syndrome","volume":"34","author":"Chambers","year":"2010","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.comppsych.2021.152244_bb0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/SLA.0b013e318288ff6d","article-title":"Cognitive impairment associated with carcinoid syndrome","volume":"259","author":"Pasieka","year":"2014","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.comppsych.2021.152244_bb0175","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3322\/caac.21285","article-title":"Psychiatric considerations in the oncology setting","volume":"65","author":"Mehta","year":"2015","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.comppsych.2021.152244_bb0180","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.cgh.2008.04.010","article-title":"Carcinoid syndrome unmasked by fluoxetine, a selective serotonin reuptake inhibitor","volume":"6","author":"Furse","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00007611-197307000-00013","article-title":"Carcinoid and psychiatric symptoms","volume":"66","author":"Major","year":"1973","journal-title":"South Med J"},{"issue":"10","key":"10.1016\/j.comppsych.2021.152244_bb0190","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1634\/theoncologist.2019-0112","article-title":"Patterns of symptoms burden in neuroendocrine tumors: a population-based analysis of prospective patient-reported outcomes","volume":"24","author":"Hallet","year":"2019","journal-title":"Oncologist."},{"key":"10.1016\/j.comppsych.2021.152244_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00025","article-title":"Living with neuroendocrine tumors: assessment of quality of life through a Mobile application","volume":"3","author":"Adams","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"9","key":"10.1016\/j.comppsych.2021.152244_bb0200","first-page":"3153","article-title":"Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours","volume":"26","author":"Beesley","year":"2018","journal-title":"Support Care Cancer"},{"issue":"40","key":"10.1016\/j.comppsych.2021.152244_bb0205","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.3748\/wjg.15.5067","article-title":"Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas","volume":"15","author":"Pezzilli","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Frojd","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0215","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.surg.2017.07.023","article-title":"Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I","volume":"162","author":"Goswami","year":"2017","journal-title":"Surgery."},{"issue":"1","key":"10.1016\/j.comppsych.2021.152244_bb0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/appi.psy.46.1.88-a","article-title":"Carcinoid tumor, selective serotonin reuptake inhibitors, and diarrhea","volume":"46","author":"Simbera","year":"2005","journal-title":"Psychosomatics."},{"issue":"11","key":"10.1016\/j.comppsych.2021.152244_bb0225","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/0284186X.2016.1182210","article-title":"May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report","volume":"55","author":"Nobels","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0230","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/02841860152703445","article-title":"Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumors","volume":"40","author":"Larrson","year":"2001","journal-title":"Acta Oncol"},{"key":"10.1016\/j.comppsych.2021.152244_bb0235","first-page":"422","article-title":"Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation","volume":"66","author":"Russo","year":"2004","journal-title":"Psychosom Med"},{"key":"10.1016\/j.comppsych.2021.152244_bb0240","first-page":"41566","article-title":"Carcinoid syndrome associated with psychosis","author":"Hanna","year":"1965","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.comppsych.2021.152244_bb0245","first-page":"292","article-title":"Psychiatric symptoms in carcinoid syndrome","volume":"82","author":"Trivedi","year":"1984","journal-title":"J Indian Med Assoc"},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0250","first-page":"29","article-title":"Neuroendocrine carcinoid cancer associated with psychosis","volume":"5","author":"Kohen","year":"2008","journal-title":"Psychiatry (Edgmont)"},{"issue":"4","key":"10.1016\/j.comppsych.2021.152244_bb0255","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1176\/appi.ajp.162.4.810-a","article-title":"Multiple endocrine neoplasia type 1 presenting as psychosis","volume":"162","author":"Kito","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"10228","key":"10.1016\/j.comppsych.2021.152244_bb0260","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(20)30324-X","article-title":"Neuropsychiatric symptoms, skin disease, and weight loss: necrolytic migratory erythema and a glucagonoma","volume":"395","author":"Boujan","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0265","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jjco\/27.6.419","article-title":"Multiple endocrine neoplasia type 1 presented with manic-depressive disorder: a case report with an identified MEN1 gene mutation","volume":"27","author":"Aoki","year":"1997","journal-title":"Jpn J Clin Oncol"},{"issue":"14","key":"10.1016\/j.comppsych.2021.152244_bb0270","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/cncr.30633","article-title":"Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome","volume":"123","author":"Shi","year":"2017","journal-title":"Cancer."},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0275","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ejso.2018.03.010","article-title":"Antidepressants appear safe in patients with carcinoid tumor: results of a retrospective review","volume":"44","author":"Isenberg-Grzeda","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.comppsych.2021.152244_bb0280","first-page":"301","article-title":"Comorbility between anxiety and depression in patients with carcinoid tumors","volume":"48","author":"Piselli","year":"2013","journal-title":"Riv Psichiatr"},{"key":"10.1016\/j.comppsych.2021.152244_bb0285","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1008360718646","article-title":"Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumors","volume":"10","author":"Larrson","year":"1999","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.comppsych.2021.152244_bb0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PPO.0000000000000067","article-title":"Sleeping in the arms of cancer: a review of sleeping disorders among patients with cancer","volume":"20","author":"Harris","year":"2014","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.comppsych.2021.152244_bb0295","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdt506","article-title":"Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice","volume":"25","author":"Howell","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.comppsych.2021.152244_bb0300","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1751-9861.2004.tb00093.x","article-title":"Depression and antidepressant use in gastrointestinal carcinoid cancer patients","volume":"9","author":"Soliday","year":"2004","journal-title":"Journal of Applied Biobehavioral Research"},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0305","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.comppsych.2021.152244_bb0310","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/pon.4681","article-title":"The generalized anxiety disorder screener (GAD-7) and the anxiety module of the hospital and depression scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients","volume":"27","author":"Esser","year":"2018","journal-title":"Psychooncology."},{"issue":"3","key":"10.1016\/j.comppsych.2021.152244_bb0315","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4067\/s0034-98872018000300300","article-title":"Assessment of the hospital anxiety and depression scale for cancer patients","volume":"146","author":"Villoria","year":"2018","journal-title":"Rev Med Chil"},{"issue":"4","key":"10.1016\/j.comppsych.2021.152244_bb0320","doi-asserted-by":"crossref","first-page":"451","DOI":"10.24869\/psyd.2017.451","article-title":"Factor structure and cut-off scores of the hospital anxiety and depression scale (HADS) in a Croatian sample of adult patients suffering from advanced cancer","volume":"29","author":"Miljanovi\u0107","year":"2017","journal-title":"Psychiatr Danub"},{"issue":"2","key":"10.1016\/j.comppsych.2021.152244_bb0325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the hospital anxiety and depression scale. An updated literature review","volume":"52","author":"Bjelland","year":"2002","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.comppsych.2021.152244_bb0330","first-page":"1","article-title":"Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review","volume":"10","author":"Isenberg-Grzeda","year":"2020","journal-title":"Palliat Support Care"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X21000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X21000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T18:36:19Z","timestamp":1757874979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X21000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":66,"alternative-id":["S0010440X21000225"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2021.152244","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2021.152244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152244"}}